Turning Complexity into Consistency: De-risked Solutions for CAR T Development and Manufacturing
- Establishing a robust, platform-based approach to T-cell process and analytical development to accelerate progression from development to GMP manufacturing while improving reliability and reproducibility
- Delivering high-titer, consistent LVV supply while eliminating complex transient transfection to enable scalable, reliable production with low replication-competent lentivirus risk
- Leveraging this integrated platform to enable lean technology transfer, a high rate of successful batch release, accelerate timelines, and deliver patient-ready outcomes